KJ-102

N/A

Report date: 2025/02/17 16:07:18

Base Information

Drug NameKJ-102

Drug Alias NameKJ-102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-PD-1Platelet glycoprotein 4 modulatorsAnti-Cluster of differentiation 47

TargetsProgrammed cell death protein 1Platelet glycoprotein 4Cluster of differentiation 47

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKisoji Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesKisoji Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A